Meeting
2021 ASCO Annual Meeting
Preclinical evaluation of the ETS inhibitor TK216 against relapsed and refractory childhood leukemia.
Authors
Ritul Sharma
University of Calgary, Calgary, AB, Canada
Ritul Sharma , Satbir Thakur , Mohit Jain , Chunfen Zhang , Anne-Marie Langevin , Aru Narendran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10033)
DOI
10.1200/JCO.2021.39.15_suppl.10033
Abstract #
10033
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: A phase Ib study.
First Author: Saad Arain
Poster
2022 ASCO Annual Meeting
Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51.
First Author: Brian Ball
Poster
2021 ASCO Annual Meeting
Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
First Author: Rajat Bannerji
Poster
2019 ASCO Annual Meeting
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.
First Author: Jessica Hochberg